{"id":245942,"date":"2012-03-29T05:03:02","date_gmt":"2012-03-29T05:03:02","guid":{"rendered":"http:\/\/www.eugenesis.com\/frost-sullivan-acclaims-targos-for-rapidly-establishing-itself-as-a-leader-in-customer-oriented-biomarker-services\/"},"modified":"2012-03-29T05:03:02","modified_gmt":"2012-03-29T05:03:02","slug":"frost-sullivan-acclaims-targos-for-rapidly-establishing-itself-as-a-leader-in-customer-oriented-biomarker-services","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/pathology\/frost-sullivan-acclaims-targos-for-rapidly-establishing-itself-as-a-leader-in-customer-oriented-biomarker-services.php","title":{"rendered":"Frost &#038; Sullivan Acclaims Targos for Rapidly Establishing Itself as a Leader in Customer-Oriented Biomarker Services &#8230;"},"content":{"rendered":"<p><p>    LONDON, March 28, 2012 \/PRNewswire\/ -- Based on its recent    analysis of the in vitro diagnostics services market, Frost    & Sullivan recognizes Targos Molecular Pathology GmbH with    the 2011 European Frost & Sullivan Award for Customer    Service Leadership. Targos is uniquely positioned to combine    expertise in clinical and molecular pathology and highly    standardised biomarker analysis with strict quality assurance.  <\/p>\n<p>    Targos has superior time lines of service compared to its    competitors, which have a turn-around-time (TAT) for not less    than four days. Targos, on the other hand, has optimized the    TAT for clinical tissue biomarker analysis to as low as 24    hours, enabling faster diagnostic test results and timely    delivery of diagnostic services.  <\/p>\n<p>    \"The Targos team has proven its meticulousness, reliability and    flexibility in handling small and very large projects to    customers' satisfaction,\" said Frost & Sullivan Research    Analyst Srinivas Sashidhar. \"It provides a wide range of    biomarker and other diagnostic services for histopathology,    tissue analysis, expression profiling, enzyme-linked    immunosorbent assay (ELISA) testing and related services    including project, data and logistic management of biomarker    studies.\"  <\/p>\n<p>    Its services and expertise have appealed to customers,    evidenced by the extension of long-term projects from 5 to 20    years. Targos' proficiency in in vitro diagnostics services has    also allowed it to expand its customer base to more than 30 top    pharmaceutical, biotech and diagnostic companies.  <\/p>\n<p>    Targos has a well-organized cost structure, which can be    tailored according to the project or service. The costs include    project management, logistics management and data management    fees. Its diagnostic service costs are lesser than its    competitors'.  <\/p>\n<p>    \"The company has been inspected by the Food and Drug    Administration (FDA) and participates in College of American    Pathologists (CAP) proficiency testing and lab improvement    programmes,\" notes Sashidhar. \"Targos, in collaboration with    its pathology partners, has acted as Good Clinical    Practice-compliant patho-diagnostic reference centre for more    than 75 pharmaco-diagnostic trials.\"  <\/p>\n<p>    Each year, Frost & Sullivan presents this award to the    company that demonstrates excellence in customer service    leadership within its industry. The recipient company shows    tremendous responsiveness to customer needs and continually    focuses on long and short-term customer profitability goals. In    addition, it demonstrates flexibility in tailoring its product    offerings to suit customer businesses.  <\/p>\n<p>    Frost & Sullivan Best Practices awards recognize companies    in a variety of regional and global markets for demonstrating    outstanding achievement and superior performance in areas such    as leadership, technological innovation, customer service and    strategic product development. Industry analysts compare market    participants and measure performance through in-depth    interviews, analysis and extensive secondary research to    identify best practices in the industry.  <\/p>\n<p>    About Targos Molecular Pathology GmbH  <\/p>\n<p>    Targos Molecular Pathology GmbH since 2005 has established    itself as a preferred service provider for standardized    analytics of clinical biomarkers. Targos central lab services    allow its customers to perform global diagnostic and    pharmaceutical approval trials under strict quality standards    and lowest possible turn-around times for molecular pathology    analyses. Targos thrives for steady improvement of service    quality and portfolio and has currently 70 employees in three    German sites.  <\/p>\n<\/p>\n<p>Originally posted here:<br \/>\n<a target=\"_blank\" href=\"http:\/\/finance.yahoo.com\/news\/frost-sullivan-acclaims-targos-rapidly-112000776.html\" title=\"Frost &amp; Sullivan Acclaims Targos for Rapidly Establishing Itself as a Leader in Customer-Oriented Biomarker Services ...\">Frost &amp; Sullivan Acclaims Targos for Rapidly Establishing Itself as a Leader in Customer-Oriented Biomarker Services ...<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p> LONDON, March 28, 2012 \/PRNewswire\/ -- Based on its recent analysis of the in vitro diagnostics services market, Frost &#038; Sullivan recognizes Targos Molecular Pathology GmbH with the 2011 European Frost &#038; Sullivan Award for Customer Service Leadership. Targos is uniquely positioned to combine expertise in clinical and molecular pathology and highly standardised biomarker analysis with strict quality assurance.  <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/pathology\/frost-sullivan-acclaims-targos-for-rapidly-establishing-itself-as-a-leader-in-customer-oriented-biomarker-services.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":57,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[577487],"tags":[],"class_list":["post-245942","post","type-post","status-publish","format-standard","hentry","category-pathology"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/245942"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/57"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=245942"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/245942\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=245942"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=245942"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=245942"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}